Skip to main content
. 2018 Jul 3;9(51):29587–29600. doi: 10.18632/oncotarget.25640

Figure 1. Anti-tumour activity of everolimus and olaparib in a BRCA2-mutated ER+ breast cancer.

Figure 1

(A) tumour growth curves of the HBCx-22 TamR xenograft treated by olaparib, everolimus and the combination. (B) waterfall plot displayed as percent of tumour volume change from baseline (each bar is an individual xenograft). (C) Western blot analysis of Histone H3 phosphorylation in HBCx22 TamR. (D) IHC analysis of Ki67 in the HBCx-22 TamR xenografts. Quantitative analysis of Ki67-positive cells was performed on technical replicates (N=5) and counting >100 nuclei. Statistical analysis of normalized P-histone H3/GAPDH and Ki67 staining between groups was performed by the unpaired t-test.*p<0.05; **p<0.005; ***p< 0.0005.